Clinical Trials

Inclusion Criteria:

1. Willing and able to provide written informed consent
2. Age ≥ 18 years
3. Diagnostic coronary angiography/left heart catheterization or percutaneous coronary intervention via the transradial approach

Exclusion Criteria:

1. Presence of a palpable hematoma or clinical concern of hemostasis at the transradial access site in which bleeding risk would be prohibitive
2. Access or attempted access site – including contralateral radial artery, brachial artery, or femoral artery or vein as switching of access could be attributed to arterial injury
3. Planned staged procedure, coronary artery bypass grafting or noncardiac surgery, within 30 days
4. Pregnant or lactating females
5. Contraindication or high risk of bleeding with anticoagulation
   1. bleeding requiring medical attention in the previous 6 months
   2. thrombocytopenia (platelets < 50 x 10^9/L)
   3. any prior intracranial hemorrhage
   4. use of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention
   5. administration of thrombolytic therapy in the preceding 24 hours
   6. use of regular non-steroidal anti-inflammatory medications excluding Aspirin < 100mg/day
   7. ischemic stroke or transient ischemic attack diagnosed in the last 3 months
6. Cardiogenic shock
7. Ventricular arrhythmias refractory to treatment
8. Liver dysfunction (Child-Pugh class B or C)
9. Unexplained anemia with a Hgb below 100 g/L
10. History of medication noncompliance or risk factor for noncompliance
11. Active malignancy
12. Allergy to rivaroxaban
13. Another indication for anticoagulation
14. Strong CYP3A4 and P-glycoprotein inhibitor use which increase rivaroxaban levels (ketoconazole, itraconazole, lopinavir/ritonavir, ritonavir, diltiazem, verapamil and conivaptan, carbamazepine, phenytoin, rifampin, St.John’s wort)
15. Life expectancy <30 days
16. Women capable of pregnancy not on birth control
17. Chronic kidney disease with creatinine clearance of less than 30mL/min
18. History of antiphospholipid syndrome, in particular triple positive (lupus anticoagulant, anticardiolipin antibodies, and anti-beta 2-glycoprotein I antibodies)

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 8/22/23. Questions regarding updates should be directed to the study team contact.